With the widespread use of antibiotics (especially third- and fourthgeneration cephalosporins and fluoroquinolones), the production of ESBLs brings challenge to the treatment of urinary infection caused by Escherichia coli with increasing resistance to common antibiotics. For the limited treatment option, the value of fosfomycin as traditional antibiotic has been reevaluated, receiving increasing attention as the cure for ESBLs-producing Escherichia coli. High susceptibility of fosfomycin and no cross-resistance with other antibiotics to multidrug-resistant Gram-negative bacteria has been reported abroad.
Wu N, Chen BY, Tian SF, Chu YZ (2015) In Vitro Susceptibility of Fosfomycin against Extended-Spectrum β-Lactamase-producing Escherichia coli Isolated from Urine Specimens. Bioenergetics 4:128.